Adjuvant therapy in pancreatic cancer

doi:10.3748/wjg.v20.i40.14733

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7291)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

476

WORD

238

HTML

3848

Tables (1-5)

237

Sum=4799

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1283

Download

1209

Sum=2492

Oct 28, 2014 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733

Table 5 Current phase III trials investigating adjuvant therapy in pancreatic cancer

Trial number	Co-ordinating country	First enrolment	Target sample size (n)	Adjuvant treatment arms	Primary outcome	Secondary outcomes (clinical only)
ISRCTN96397434	United Kingdom	2008	1396	(I) Gemcitabine	OS	Toxicity
(ESPAC-4)				(II) Gemcitabine plus capecitabine		Quality of life
						OS at 2 and 5 yr
						DFS at 5 yr
DRKS00000247	Germany	2008	436	(I) Gemcitabine	DFS	OS
(CONKO-005)				(II) Gemcitabine plus erlotinib		Toxicity
NCT01013649	United States	2009	950	(I) Gemcitabine	OS	DFS
(RTOG 0848)				(II) Gemcitabine plus erlotinib		Toxicity
				If DFS at end of treatment (I) or (II), further randomisation to:		Correlation between baseline fatigue and survival
				(III) A further course of (I) or (II) as previously received plus Capcitabine CRT
				(IV) A further course of (I) or (II) as previously received plus 5-FU CRT
NCT01072981	United States	2010	722	Gemcitabine +/- 5-FU CRT +/- HyperAcute^®-Pancreas (algenpantucel-L) immunotherapy	OS
NCT01526135	France/Canada	2012	490	(I) Gemcitabine	DFS at 3 yr	OS at 3 yr
				(II) mFolfirinox (5-FU, folinic acid, irinotecan, oxaliplatin)
NCT01077427	Germany	2012	336	(I) Gemcitabine	DFS	OS
				(II) Gemcitabine plus cisplatin plus regional hyperthermia
NCT01964430	United States	Not yet active	-	(I) Gemcitaine	DFS/OS
				(II) Gemcitabine plus nab-paclitaxel

OS: Overall survival; DFS: Disease-free survival; CRT: Chemoradiotherapy; 5-FU: 5-flurouracil.

Citation: Jones OP, Melling JD, Ghaneh P. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14733-14746
URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14733.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14733